Eisai (company)

Eisai Co., Ltd. (Japanese: エーザイ株式会社) is a global pharmaceutical company and the world's 23rd largest pharmaceutical company by revenue. The company was established in 1941 and has its headquarters in Tokyo, Japan. Eisai's areas of business include neuroscience, oncology, vaccines and veterinary medicine.

History[edit | edit source]

Eisai was founded in 1941 by Toyoji Naito and his wife, in a time when access to healthcare was limited in Japan. The company was named after the ancient Chinese medical text, the "Huangdi Neijing" (Inner Canon of the Yellow Emperor), from which the character "Eisai" was taken.

Business Areas[edit | edit source]

Eisai's primary areas of business are neuroscience and oncology, as well as vaccines and veterinary medicine. The company has developed and marketed a number of notable drugs, including Aricept for Alzheimer's disease, Halaven for breast cancer, and Lenvima for thyroid cancer.

Research and Development[edit | edit source]

Eisai is committed to the development of innovative drugs, with a focus on diseases with high unmet medical needs. The company's research and development efforts are focused on neuroscience, oncology, and vascular/immunological reaction.

Global Presence[edit | edit source]

Eisai has a global presence with manufacturing plants and research facilities in countries around the world, including the United States, United Kingdom, China, and India.

Social Responsibility[edit | edit source]

Eisai is committed to improving global health through innovative drug development and global outreach programs. The company's social responsibility initiatives include efforts to combat neglected tropical diseases and improve access to medicines in developing countries.